Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial

BACKGROUND: No therapies have been proven to persistently improve the outcome of HTLV-I-associated myelopathy. Clinical benefit has been reported with zidovudine and with lamivudine in observational studies. We therefore conducted a randomised, double blind, placebo controlled study of six months co...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Graham P, Goon, Peter, Furukawa, Yoshitaka, Green, Hannah, Barfield, Anna, Mosley, Angelina, Nose, Hirohisa, Babiker, Abdel, Rudge, Peter, Usuku, Koichiro, Osame, Mitsuhiro, Bangham, Charles RM, Weber, Jonathan N
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1590049/
https://www.ncbi.nlm.nih.gov/pubmed/16984654
http://dx.doi.org/10.1186/1742-4690-3-63

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1590049/
https://www.ncbi.nlm.nih.gov/pubmed/16984654
http://dx.doi.org/10.1186/1742-4690-3-63

Ejemplares similares